Evidence map›Paper›PMID 31242951›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer.

Marianna Buttarelli, Gabriele Babini, Giuseppina Raspaglio, Flavia Filippetti, Alessandra Battaglia, Alessandra Ciucci, Gabriella Ferrandina, Marco Petrillo, Carmela Marino, Mariateresa Mancuso and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.Journal of experimental & clinical cancer research : CR · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Marianna ButtarelliUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Gabriele BabiniDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Giuseppina RaspaglioUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Flavia FilippettiUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Alessandra BattagliaIstituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Rome, Italy.
Alessandra CiucciUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Gabriella FerrandinaIstituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Rome, Italy.
Marco PetrilloIstituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Rome, Italy.
Carmela MarinoDivision of Health Protection Technology, Department for Sustainability, National Agency for Energy, New Technologies and Sustainable Economic Development (ENEA), Rome, Italy.
Mariateresa MancusoDivision of Health Protection Technology, Department for Sustainability, National Agency for Energy, New Technologies and Sustainable Economic Development (ENEA), Rome, Italy.
Anna SaranDivision of Health Protection Technology, Department for Sustainability, National Agency for Energy, New Technologies and Sustainable Economic Development (ENEA), Rome, Italy.
Maria Elena VillaniDivision of Biotechnologies and Agroindustry, Department for Sustainability, National Agency for Energy, New Technologies and Sustainable Economic Development (ENEA), Rome, Italy.
Angiola DesiderioDivision of Biotechnologies and Agroindustry, Department for Sustainability, National Agency for Energy, New Technologies and Sustainable Economic Development (ENEA), Rome, Italy.
Chiara D'AmbrosioProteomics and Mass Spectrometry Laboratory, ISPAAM-National Research Council, Naples, Italy.
Andrea ScaloniProteomics and Mass Spectrometry Laboratory, ISPAAM-National Research Council, Naples, Italy.
Giovanni ScambiaIstituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Rome, Italy.
Daniela GalloUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. daniela.gallo@unicatt.it.
Università Cattolica del Sacro Cuore · ITNational Agency for New Technologies, Energy and Sustainable Economic Development · ITAgostino Gemelli University Polyclinic · ITNational Research Council · IT

Funding

Regione Campania PO FESR 2014-2020
6 · The paper itself

Abstract

backgroundA better understanding of locally advanced cervical cancer (LACC) is mandatory for further improving the rates of disease control, since a significant proportion of patients still fail to respond or undergo relapse after concurrent chemoradiation treatment (CRT), and survival for these patients has generally remained poor.

methodsTo identify specific markers of CRT response, we compared pretreatment biopsies from LACC patients with pathological complete response (sensitive) with those from patients showing macroscopic residual tumor (resistant) after neoadjuvant CRT, using a proteomic approach integrated with gene expression profiling. The study of the underpinning mechanisms of chemoradiation response was carried out through in vitro models of cervical cancer.

resultsWe identified annexin A2 (ANXA2), N-myc downstream regulated gene 1 (NDRG1) and signal transducer and activator of transcription 1 (STAT1) as biomarkers of LACC patients' responsiveness to CRT. The dataset collected through qPCR on these genes was used as training dataset to implement a Random Forest algorithm able to predict the response of new patients to this treatment. Mechanistic investigations demonstrated the key role of the identified genes in the balance between death and survival of tumor cells.

conclusionsOur results define a predictive gene signature that can help in cervical cancer patient stratification, thus providing a useful tool towards more personalized treatment modalities.

Indexed as

AdultAgedAnnexin A2Antineoplastic AgentsBiomarkers, TumorCell Cycle ProteinsChemoradiotherapyCisplatinFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMiddle AgedNeoadjuvant TherapyN-myc Downstream-Regulated Gene 1 ProteinPoly (ADP-Ribose) Polymerase-1Annexin A2Antineoplastic AgentsANXA2 protein, humanBiomarkers, TumorCell Cycle ProteinsCisplatinIntracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 ProteinPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1STAT1 protein, humanSTAT1 Transcription FactorCervixLACCMolecular biomarkersPersonalized medicineProteomics

Identifiers

PMID31242951
PMCPMC6595690
OpenAlexW2954775314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.